UnitedHealth Group releases results of independent audit
UnitedHealthcare sign is displayed at its office building in Minnetonka, Minnesota, U.S., Dec. 11, 2025. Tim Evans |…
Pharma’s ‘Dr. Optimistic’ is worried about the industry’s future
In July 2006, The New York Times sent young reporter Alex Berenson to Pfizer to interview me about…
FDA voucher program has led to political interference in drug reviews, staffers say
WASHINGTON — A new program intended to fast-track drug reviews at the Food and Drug Administration is quickly…
Meta urged by state AGs to regulate weight loss drug ads
More than three dozen state attorneys general are urging Meta to better enforce its policies to thwart a…
Clinical Update’s year in review
What clinical stories dominated the headlines and captured our attention in 2025? Dive in and find out! The…
Research Reveals How Disordered Protein Regions Contribute to Cancer-Causing Condensates
Newswise — (MEMPHIS, Tenn. – December 3, 2025) Fusion oncoproteins arise when a gene fuses with another gene…
Long-Term Antidepressant Use Surges in Australia, Sparking Warnings of Overprescribing
Newswise — Long-term antidepressant use in Australia has risen steadily over the past decade, with the largest increase…
WHO backs use of GLP-1 therapies for obesity, warns access will remain limited
A view shows The World Health Organization (WHO) headquarters in Geneva, Switzerland, Jan. 28, 2025. Denis Balibouse |…
Lilly cuts price for obesity drug Zepbound
Trump announces lower prices coming for GLP-1 drugs Zepbound, Wegovy President Donald Trump announces discounted pricing for Zepbound…
Japan to accelerate talks over revision to medical service fees
Japan is set to begin full-fledged discussions on revising medical service fees, which are set by the government…
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET,…
Novo Nordisk stumbles against Eli Lilly in GLP-1 drug battle. Which stock is best?
In the battle between weight-loss drug companies, Eli Lilly has emerged as the clear winner for investors. The…